Plk1与p21WAF1/CIP1在肝细胞癌中的表达

目的 细胞周期抑制因子p21<'WAF1/CIP1>(p21)可在转录水平抑制Polo-like kinase1(Plk1)基因的表达,本文旨在探讨Plk1和p21蛋白在肝细胞癌中的表达及相关性.方法 应用Westem Blot方法检测10对原发性肝细胞癌和癌旁组织中Plk1和p21蛋白的表达情况.通过将pFlex-21表达质粒瞬时转染人肝癌细胞系HepG2细胞,进一步检测p21过表达对Plk1mRNA和蛋白表达的影响.结果 Plk1在10例肝癌组织中的表达均高于配对癌旁组织,p21蛋白在7对肝癌组织中的表达高于配对癌旁组织.HepG2细胞瞬时表达p21质粒后,Plk1的蛋白表达和mRNA水平均无变化(P>0.05).结论 Plk1和p21在肝细胞癌组织中的表达具有一定的肿瘤特异性.肝癌组织中p21蛋白过表达可能不具有抑制Plk1表达的作用,具体机制还有待于进一步研究.     

Relationship of p21WAF1/CIP1/SDI1 to cell proliferation in primary cultures of adrenocortical cells

p21^{WAF1/CIP1/SDI1} was originally described as a protein expressed at high levels in senescent human fibroblasts. We have studied the expression of p21 in adrenocortical cells, p21 is not expressed under most circumstances in the intact adrenal gland in vivo, except when the gland is damaged. When human and bovine adrenocortical cells are isolated and placed in both short-term and long-term culture, p21 levels are much higher. These levels did not show a large increase when the cells senesce after long-term proliferation. Thus, these observations raise the question of whether the elevated p21 in primary cultures of adrenocortical cells is caused by damage or whether p21 is elevated because the cells are dividing rather than quiescent, because it has been reported that p21 levels peak in G1 and G2 in dividing cells. In the present experiments on bovine and human adrenocortical cells in primary culture, labeling techniques that correlated nuclear p21 with measures of cell proliferation (bromodeoxyuridine incorporation and nuclear Ki-67 antigen) supported the hypothesis that p21 is associated with cell division and not with damage. This is consistent with recent data showing that, when adrenocortical cells are transplanted into immunodeficient mice, p21 is associated with healthy dividing cells in the transplant, p21 is not a unique marker for senescence, and more studies are required both to clarify its role in cell biology and to determine molecular features which characterize the senescent state of cells both in vitro and in vivo.     

ATP-dependent activation of p21WAF1/CIP1-associated Cdk2 by Cdc6

When cells progressing in mid-S phase are damaged with a base-modifying chemical, they arrest in S phase long after the CHK1 checkpoint signal fades out, partly because of p53-mediated long-lasting induction of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1). We have recently found that enforced expression of Cdc6, the assembler of prereplicative complexes, markedly advances recovery from the prolonged S-phase arrest and reactivation of Cdk2 despite the presence of a high level of induced p21. Here, we report that Cdc6 protein can activate p21-associated Cdk2 in an ATP-dependent manner in vitro. Consistently, Cdc6 mutated for ATPase or a putative cyclin binding motif is no longer able to activate the Cdk2 in vitro or promote reinitiation of S-phase progression and reactivation of Cdk2 in vivo. These results reveal the never anticipated function of Cdc6 and redefine its role in the control of S-phase progression in mammalian cells.     

p21~(WAF1/CIP1/SDI1)在大鼠肾脏组织的增龄性变化及意义

目的 研究p21野生型p53活化片段1/细胞周期蛋白依赖性激酶影响蛋白1/衰老细胞衍生抑制剂1(p21WAF1/CIP1/SDI1)在大鼠肾脏中随年龄增长的表达变化规律. 方法 取3月龄、12月龄及24月龄健康雄性Wistar大鼠肾组织进行衰老相关β-半乳糖苷酶(SA-β-gal)活性染色,TUNEL法检测细胞凋亡,采用逆转录多聚酶链反应(RT-PCR)和Western印迹法(Western blot assay)分别在基因及蛋白质表达水平上检测肾脏组织中p21WAF1/CIP1/SDI1的表达变化,并用免疫组化法检测p21WAF1/CIP1/SDI1在肾脏组织中的表达与定位. 结果 大鼠肾脏组织SA-β-gal活性随年龄增长逐渐增强,凋亡细胞也随年龄增长逐渐增加(P＜0.05);p21WAF1/CIP1/SDI1 mRNA表达随年龄增长逐渐增强,不同月龄比较差异有统计学意义(P＜0.05).Western印迹亦显示p21WAF1/CIP1/SDI1蛋白表达随鼠龄增加逐渐增强(P＜0.05).免疫组化结果显示,p21WAF1/CIP1/SDI1蛋白表达于大鼠肾小球足细胞,其在肾小管与间质细胞中也有表达,且随年龄增长表达增加(P＜0.05). 结论 p21WAF1/CIP1/SDI1在大鼠肾脏组织中的表达随年龄增加而增强,可作为肾脏组织中重要的衰老指标.     

Plkl与p21~（WAF1/CIP1）在肝细胞癌中的表达

目的细胞周期抑制因子p21WAF1/CIP1（p21）可在转录水平抑制Polo-like kinase1（Plk1）基因的表达,本文旨在探讨Plk1和p21蛋白在肝细胞癌中的表达及相关性。方法应用Western Blot方法检测10对原发性肝细胞癌和癌旁组织中Plk1和p21蛋白的表达情况。通过将pFlex-p21表达质粒瞬时转染人肝癌细胞系HepG2细胞,进一步检测p21过表达对Plk1mRNA和蛋白表达的影响。结果 Plk1在10例肝癌组织中的表达均高于配对癌旁组织,p21蛋白在7对肝癌组织中的表达高于配对癌旁组织。HepG2细胞瞬时表达p21质粒后,Plk1的蛋白表达和mRNA水平均无变化（P〉0.05）。结论 Plk1和p21在肝细胞癌组织中的表达具有一定的肿瘤特异性。肝癌组织中p21蛋白过表达可能不具有抑制Plk1表达的作用,具体机制还有待于进一步研究。     

p21WAF1/CIP1 基因转染对胃癌细胞生物学活性的影响

目的探讨p21^WAF1／CIP1基因(p21基因)对人胃癌细胞系(BGC)生物学活性的影响。方法应用分子克隆技术构建p21^WAF1／CIP1基因真核表达载体，然后用脂质体法将其导入到人胃癌细胞BGC中，经G418筛选获得可稳定表达p21^WAF1／CIP1的人胃癌细胞克隆，用中性红摄入法观察细胞生长速率，流式细胞仪(FcM)检测细胞周期变化。结果p21导入胃癌BGC细胞后，肿瘤细胞增值能力明显受到抑制，并出现细胞周期G1期阻滞。结论p21基因具有抑制胃癌细胞增殖的作用，可作为胃癌基因治疗的靶基因．     

Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells

Estrogens and antiestrogens influence the G(1) phase of the cell cycle. In MCF-7 breast cancer cells, estrogen stimulated cell cycle progression through loss of the kinase inhibitor proteins (KIPs) p27 and p21 and through G(1) cyclin-dependent kinase (cdk) activation. Treatment with antiestrogen drugs, Tamoxifen or ICI 182780, caused cell cycle arrest, with up-regulation of both p21 and p27 levels, an increase in their binding to cyclin E-cdk2, and kinase inhibition. The requirement for these KIPs in the arrests induced by estradiol depletion or by antiestrogens was investigated with antisense. Antisense inhibition of p21 or p27 expression in estradiol-depleted or antiestrogenarrested MCF-7 led to abrogation of cell cycle arrest, with loss of cyclin E-associated KIPs, activation of cyclin E-cdk2, and S phase entrance. These data demonstrate that depletion of either p21 or p27 can mimic estrogen-stimulated cell cycle activation and indicate that both of these KIPs are critical mediators of the therapeutic effects of antiestrogens in breast cancer.     

Cell cycle inhibition by the anti-angiogenic agent TNP-470 is mediated by p53 and p21WAF1/CIP1

Angiogenesis has been demonstrated to be essential for tumor growth and metastasis, and inhibition of angiogenesis is emerging as a promising strategy for treating cancer. Among the most potent inhibitors of angiogenesis is the fumagillin family of natural products. An analog of fumagillin, known as TNP-470 or AGM-1470, has been undergoing clinical trials for treating a variety of cancers. TNP-470 has been shown to block endothelial cell cycle progression in the late G(1) phase. Although the direct molecular target for TNP-470 has been identified as the type 2 methionine aminopeptidase (MetAP2), how inhibition of this enzyme leads to cell cycle arrest has remained unclear. We report that treatment of endothelial and other drug-sensitive cell types leads to the activation of the p53 pathway, causing an accumulation of the G(1) cyclin-dependent kinase inhibitor p21(WAF1/CIP1). The requirement of p53 and p21(WAF1/CIP1) for the cell cycle inhibition by TNP-470 is underscored by the observation that cells deficient in p53 and p21(WAF1/CIP1) are resistant to TNP-470. These results shed significant light on the mechanism of cell cycle inhibition by TNP-470 and suggest an alternative method of activating p53 in endothelial cells to halt angiogenesis and tumor progression.     

The antiangiogenic agent TNP-470 requires p53 and p21CIP/WAF for endothelial cell growth arrest

Targeting the endothelial cell cycle as an antiangiogenic strategy has been difficult given the ubiquitous expression of critical cell cycle regulators. Here, we show that the antiangiogenic drug TNP-470 displays striking cell-type specificity insofar as it induces the expression of p21(CIP/WAF), a cyclin-dependent kinase inhibitor, in endothelial cells but not in embryonic or adult fibroblasts. Moreover, primary endothelial cells isolated from p53(-/-) and p21(CIP/WAF-/-) mice are resistant to the cytostatic activity of TNP-470. We also demonstrate that p21(CIP/WAF-/-) mice are resistant to the antiangiogenic activity of TNP-470 in the basic fibroblast growth factor corneal micropocket angiogenesis assay. We conclude that TNP-470 induces p53 activation through a unique mechanism in endothelial cells leading to p21(CIP/WAF) expression and subsequent growth arrest.     

Venous invasion and down-regulation of p21(WAF1/CIP1) are associated with metastasis in colorectal carcinomas

BACKGROUND/AIMS: Liver and lymph node metastasis the major prognostic factor in patients with colorectal carcinoma. The aim of this work was to search for tumor parameters which can be employed to predict whether this has occurred. METHODOLOGY: A total of 211 patients with a colorectal carcinoma (Dukes' B group, 83; Dukes' C, 94; Dukes' D, 34) were investigated for 10 clinicopathological variables, as well as apoptotic activity, expression of Ki-67, p21(WAF1/CIP1), p53, bcl-2 and DCC proteins, and the c-Ki-ras mutations. Data were analyzed by univariate and multivariate statistics. RESULTS: Lymph node metastasis-predictive models were developed using the venous involvement index (the number of vascular involvements per elastica van Gieson-stained slide; Odds ratio [OR], 2.38; 95% confidence interval [CI], 1.52-3.71; p=0.0001), tumor size (OR, 0.82; 95% CI, 0.70-0.97; p=0.0179), and p21(WAF1/CIP1) immunolabeled index (the percentages of positive tumor cells; OR, 0.76; 95% CI, 0.64-0.90; p=0.0011). Liver metastasis-predictive models were developed using the venous involvement index (OR, 2.40; 95% CI, 1.71-3.37; p=0.0000) and tumor location (rectum vs. colon; OR, 9.31; 95% CI, 2.41-36.01; p=0.0012). CONCLUSIONS: Down-regulation of p21(WAF1/CIP1) as well as marked venous involvement, small tumor size and colonic tumor are associated with lymph node and/or liver metastasis. Criteria for assessment of metastasis risk provide a basis for additional treatment guidelines.     

KLF6、p21^WAF1/CIP1、CyclinD1在结直肠癌中的表达及意义

目的研究转录因子KLF6、p21WAF1/C IP1及Cyc linD1在结直肠癌中的表达及意义。方法应用免疫组化Envision法对58例结直肠癌组织、20例结直肠黏膜慢性炎症组织中的KLF6、p21WAF1/C IP1及Cyc linD1蛋白表达进行检测。结果结直肠癌组织KLF6、p21WAF1/C IP1及Cyc linD1蛋白表达率均与结直肠黏膜慢性炎症组织比较有统计学差异（P〈0.05）;KLF6、p21WAF1/C IP1及Cyc linD1蛋白在结直肠癌组织中的表达与其浸润深度及预后有关（P〈0.05）。结论 KLF6、p21WAF1/C IP1及Cyc linD1在结直肠癌的发生发展中可能起重要作用。     

Relationship between K-ras mutation and the expression of p21WAF1/CIP1 and p53 in chronic pancreatitis and pancreatic adenocarcinoma

Overexpression of p21WAF1/CIP1 was recently described as an early event in the development of pancreatic intraepithelial neoplasia. Since activating K-ras mutations are described in more than 80% of pancreatic cancers and are known to increase intracellular levels of p21WAF1/CIP1 in experimental models, the possible role of activating K-ras mutations in an induction of the p21WAF1/CIP1 expression was investigated in our study. We examined 71 surgical specimens, 29 of chronic pancreatitis and 42 of invasive ductal adenocarcinoma both having a large spectrum of PanIN (pancreatic intraepithelial neoplasia) lesions. Expression of p53 and p21WAF1/CIP1 was examined immunohistochemically and codon 12 K-ras mutational analysis was performed using the very sensitive mutant-enriched PCR-RFLP (polymerase chain reaction-restriction fragment length polymorphism) analysis. Our study demonstrated the overexpression of p21WAF1/CIP1 as an early event in the development of pancreatic intraepithelial neoplasia in the group of chronic pancreatitis and invasive adenocarcinoma as well. Overexpression of p21WAF1/CIP1 increased progressively from normal ducts through the spectrum of PanIN lesions to invasive carcinomas. The p53 overexpression increased again progressively according to the severity of the lesion and seems to be a later event in the development of pancreatic intraepithelial neoplasia if compared to p21WAF1/CIP1 expression. Our results confirmed also the possible p53 independent p21WAF1/CIP1 expression in some PanIN2, PanIN3 lesions and invasive carcinomas. K-ras mutations were not revealed in samples with only low grade PanIN lesions (PanIN1a and PanIN1b). K-ras mutations were detected in 69,4% adenocarcinomas and in only one case of chronic pancreatitis. Two codon 12 K-ras positive pancreatic carcinomas showed K-ras mutations in the surrounding normal pancreatic tissue. In adenocarcinomas, no statistically significant correlation was found between K-ras mutational status and p21WAF1/CIP1 and p53 expression, respectively. The possible role of activating K-ras mutations in an induction of p21WAF1/CIP1 expression was not confirmed in this study.